Thank you for posting something so positive. The stock
Thank you for posting something so positive. The stock price going up is getting old with all those thousands of dollars a day of increases. It hard to accept all that money from making this investment with CYDY. Just kidding...
Who would of believed that you could see over 10x your money in a year with a great chance to see another 10x increase in just this next couple of months? I am looking forward to all the toys and boats and muscle cars and throw in vacation home/early retirement home in my future. Waiting a whole 2 or 3 more and years for the big money just seems much smarter and to ride out all the good news we will hear about this conference call sets up the future triple digit stock surges from every indication we see get a BLA. One right after another. Hmmmm...
I found it amusing today reading about the GVHD mice test. Nader told us almost a year ago that our results were twice as good as the leading company. He didn’t tell us that it was a cure like the Seeking Alpha article stated. The test on the mice was so good that they didn’t have one mouse die from the stem cell injection. When normally all would die. It was so unbelievable that they couldn’t believe it and performed the test again. This my friends, is a good sign! No... it’s a great sign. You could almost hear it getting better. Do you hear it? Cha Ching! Cha Ching. It’s early I know but it just smells of money for GVHD. These results must of made our doctors think they could use it in bone marrow transplants and to cure HIV? Hence the testing we are now trying.
I just have to say that what kind of drug has so many damn indications that looks like the next best thing to happen for mankind? To have found this investment is truly a blessing and a good friend steered me to Leronlimab. I have also steered friends and family to invest and update them with breaking news daily whether good or bad. Lately almost everything is good. The shorts haven’t been lying as much. Just trying to exploit something that isn’t real but not an outright lie like they have in the past. The shorts seem to buy together and sell together and short our little stock. Their conscience must be hurting from delaying this drug from an approval we would of probably had a few months ago had we had no stock manipulation and slowed our little company down. We would of looked good to many on our record of our trials for HIV and had a stock price based on our future indications and possibilities and be maybe 3-5 times our current stock price if we wouldn’t of had all the abuse of the shorts. It really did slow down what would of saved many many lives. Shorting CYDY was essentially responsible for some of our slow progression which undoubtedly adds blood on their hands. You would think that lives were more important than the money. It is for some. Just not for all. Me personally... I have not sold a share since I first bought CYDY over a year ago.
My conscience is clear. I feel as a dedicated investor I am helping to save lives. What does someone feel that profits from the shorting? Do you still feel your saving lives? Do you justify making money over lives? Is there a way to justify those few extra dollars? I don’t see it personally.
6
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
What's Really Going On Here? Here's the skinny: Halper Sadeh LLC, that hard-hitting investor rights law firm, is poking their noses into some potential red flags over at a few companies you might have heard of—Lumentum Holdings (NASDAQ:LITE), Range Resources (NYSE:RRC), and Surgery Partners (NASDAQ:SGRY). They're sniffing around transactions that might leave the regular...
Continue Reading
Transfer Online Teams Up with OnchainTA Hold onto your investment hats, folks—Transfer Online is linking arms with OnchainTA to step right into the future playground of tokenized securities. Now, what's that mean? Well, it's like jumping from sailing schooners to speedboats; we're entering a whole new era in capital markets. What's At Stake? The pair-up between these...
Continue Reading
The Battle Begins: Cboe's Legal Action Cboe Global Markets, the big kahuna in the equities and index derivatives scene, ain't just rolling over quietly. They've hopped on board with the Capital Markets Alliance in a legal dust-up against the Commodity Futures Trading Commission's (CFTC) decision to allow perpetual derivatives on U.S. stocks and ETFs. We're talking major...
Continue Reading
Dividend Declaration Reflects Confidence First Industrial Realty Trust, folks, just put another office stamp on their ongoing reliability quest—and I'm talking dividends. They're shelling out a tidy $0.50 per share for Q4 2026, with stockholders due to see the cash on January 19, 2027. That's like clockwork precision, showing a steadiness in what some call the unruly...
Continue Reading
Market Set to Boom: $56.99 Billion by 2031 Grab your coffee and take a seat—this isn't your usual healthcare spiel. The healthcare consulting services market's cruising down a rapid growth highway, projected to tap dance to a whopping $56.99 billion by 2031, starting from $35.55 billion last year. We're talking a solid 9.9% CAGR, folks. Now, anytime numbers stack this...
Continue Reading
Shaking Up the Holiday Gifting Game You ever feel like holiday gifting is stuck in a rut? Same old generic bottles and baskets. But, here comes Eunice Chiweshe Goldstein Winery, charging in with a fresh take on holiday generosity. This ain't just about selling wine—this is about crafting an experience for both giver and receiver. Perfect for those looking to ditch the...
Continue Reading
Micropos Medical's Bold Steps into Radiotherapy Let's put a spotlight on a niche that's crying for attention: Micropos Medical is making waves in how we treat prostate cancer. They're leveraging technology with their Raypilot System, and they're partnering with the big guns at Johns Hopkins Medicine. Think about it — five patients in the U.S. are already seeing how this...
Continue Reading
Paving the Future with Patents Ah, patents. Like stock dividends for the tech world—they don’t change everything outright but can signal some mighty good things ahead. This time around, it’s Satisfi Labs who are in the spotlight. They’ve bagged not one, but two shiny U.S. patents to bolster what they’re calling Satisfi Forward. Honestly, it sounds like a...
Continue Reading
Mac Cummings: A Maverick at Terakeet's Helm So, here’s the deal—we’ve got Mac Cummings, a guy who's shaking up the marketing world just when we thought we had it all figured out. When you get a nod from ADWEEK's Innovator 50, it isn't because you played it safe. It's because you believed in disrupting the status quo. Cummings has taken Terakeet from a humble start...
Continue Reading
Solid-State Dreams Meet AI Magic Ah, the sweet sound of synergy. ISU Specialty Chemical and Ares Materials are brewing up something that could shake the battery world—solid-state cells juiced by AI-driven polymer magic. Now, the tech and finance geeks are likely on the edge of their seats. This isn't just another run-of-the-mill collab; it's a heavyweight match to speed...
Continue Reading
Top 5 Most Recently Viewed Articles
Bluerock High Income Fund Announces Latest Financial Updates Bluerock High Income Institutional Credit Fund, a notable player in the investment landscape, has recently revealed its quarterly distribution figures. Currently, the Fund is set to distribute approximately $0.52 per share, which translates to a remarkable 9.0% annualized distribution rate. This latest...
Continue Reading
Airlink Inc. Welcomes New Leadership for 2025-2027 Airlink, Inc. is excited to introduce its new Board of Trustees members for the upcoming term, bringing a wealth of experience across diverse fields crucial to the aviation sector. This year's board welcomes six new members whose backgrounds span law, engineering, technology, and international relations, perfect for...
Continue Reading
MindHYVE.ai™ Demonstrates ChironAI™ at Leading CME Event MindHYVE.ai™ recently made an impactful appearance at a prestigious Continuing Medical Education (CME) session focused on innovations in cardiovascular imaging. The event gathered a variety of healthcare professionals including senior cardiologists, radiologists, and imaging specialists from various regions,...
Continue Reading
UBS Adjusts Price Target for McDonald's Stock McDonald's Corporation (NYSE: MCD) has recently captured the attention of investors, as UBS has raised its price target on the fast-food giant's stock from $305 to an impressive $345. This revision is buoyed by strong sales growth potential that the company is expected to experience through the end of 2024 and into 2025. With...
Continue Reading
Understanding the Kroger-Albertsons Merger Situation The legal proceedings surrounding the merger between Kroger and Albertsons have the potential to reshape the grocery industry considerably. This courtroom battle is crucial, as it involves the largest supermarket merger proposal in U.S. history, raising numerous concerns from both consumers and investors. Initially...
Continue Reading